p REOPERATIVE treatment of ruptured aneurysms is aimed at controlling the risk of rebleeding during the early period following surgery, so as to reduce the arterial spasm and improve the patient's general condition. 7 At present, therapeutic weapons against arterial spasm produced by subarachnoid hemorrhage (SAH) are only partially successful. Several authors, however, have achieved important reduction in the recurrence rate of hemorrhage with antifibrinolytic therapy, a,9,1~ 15,~s.~9
It has been suggested that localized flbrinolysis in the cerebrospinal fluid (CSF) may play a role in the early dissolution of the initial fibrin plug, thus leading to rebleeding. ~7 In the present study, fibrinolytic activity in a group of patients with SAH was monitored simultaneously in CSF and blood by testing the levels of fibrin split products (FSP). The results are compared in patients with and without antifibrinolytic treatment.
Clinical Material and Methods
The study included 23 patients with SAH due to ruptured intracranial aneurysms. Eleven of these received antifibrinolytic therapy. They underwent surgery in the 3rd week after SAH or later. Lumbar punctures were performed every 6 days in order to determine levels of FSP, which reflect fibrinolysis. Levels of FSP were simultaneously determined in plasma.
The fibrinolysis-inhibitor agent we employed was tranexamic acid (transaminoethylcyclohexane carboxylic acid, AMCA), administered intravenously in doses of 500 mg every 6 hours during the first 6 days of treatment, followed by oral doses up to the time of the operation. The therapy was started immediately after the first FSP determination. A control group consisted of 12 patients who had been submitted to lumbar puncture as a diagnostic procedure and who had been found to suffer no organic pathology. The CSF thus obtained was then studied.
The FSP values were determined by agglutination on latex particles? Samples of both blood and CSF were collected in glass tubes with thrombin and antifibrinolytic agents in order to induce coagulation and to prevent fibrinolysis in vitro. Samples were incubated at 37~ for 60 minutes and then determinations were made. In every patient a thorough study of clotting mechanisms was carried out in order to exclude cases of hemorrhage due to hemostatic impairment. A standard test was used, including platelet count, fibrinogen test, coagulation time, prothombin j. A. Alvarez Garijo, J. J. Vilches and J. A. Aznar time, clot retraction time, cefalin-kaolin time, and test for factors V, VII, VIII, and IX. Table 1 shows the results for patients who were treated with tranexamic acid and those who were not. In all but two cases in which no treatment was given, fibrinolytic activity was found in the CSF during the 2nd week, even in those cases in which it had been completely absent during the 1st week. On the other hand, this activity was observed in only two of the treated patients during the 2nd week, while in the rest there was no FSP activity.
Results
Two of the 12 untreated patients suffered another hemorrhage, and in both of them there was FSP in the CSF. Among those who received treatment, rebleeding occurred in one of the two patients in whom fibrinolytic activity was found during the 2nd week. In no case were there changes in peripheral blood flow. Figure 1 shows the average curve of FSP levels in treated and untreated patients. This curve clearly demonstrates the benefits of this therapy. There were no changes in the CSF of control patients. It has been claimed that antifibrinolytic treatment might be followed by thromboembolic complications. TM Therefore, there is a need for a method to assess the results of the therapy and, at the same time, to minimize its possible risks.
Geronemus, et al., 4 and Smith and Upchurch ~5 first monitored antifibrinolytic treatment in cases of SAH. The former authors measured results of therapy by the determination of streptokinase clot lysis, and the latter by the fibrin plate method. These methods supply information about systemic fibrinolysis and the blood stream, but not about the CSF, where, as demonstrated by Tovi, et al., [7] [8] [9] and supported by our results, a local fibrinolytic process starts after SAH. Furthermore, increased fibrinolytic activity in the CSF is not necessarily reflected in peripheral blood. In none of our patients was the increased FSP level in the CSF accompanied by a rise of FSP level in the blood.
It is not yet clear how the CSF fibrinolytic activity therapy with tran-12 patients were is triggered, as this process requires the existence of tissue plasminogenic activators and the plasminogen itself. The former have been found in nervous tissue and were especially abundant in the meninges and choroid plexus. 8,17 On the other hand, plasminogen is normally confined to plasma, and it only reaches the CSF when it is infiltrated by blood or in pathological situations that alter the blood-brain barrier? ,2~
Authors have reported using EACA in doses of 24 to 36 gm/24 hrs and AMCA at 6 gm daily as antifibrinolytic agents. Both are able to cross the bloodbrain barrier and subsequently inhibit focal fibrinolysis, but the human CSF pharmacodynamic properties of EACA have not yet been precisely determined, as Tovi, et al., Is'~9 have done with AMCA. It should be noted that Tovi observed a progressive rise of AMCA concentration in the CSF with successive doses, while in plasma it reached a steady level.
The dose of 2 gm of AMCA employed by us proved to be effective in inhibiting CSF fibrinolysis in all but two of the treated cases. In retrospect, an increase of the drug doses in these two patients might have been prescribed. The question that arises is whether it is necessary to expose to an additional risk those patients in whom lower doses of antifibrinolytic agent FIG. 1. Levels of fibrin split products in the cerebrospinal fluid expressed in ug/100 ml in 23 patients with subarachnoid hemorrhage. The average curve is shown in untreated patients (U) and patients treated with tranexamic acid (T).
are efficacious. This controversy might be overcome by routinely monitoring fibrinolytic activity in the CSF and making corrections of dosage according to individual requirements.
